🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07651475
Active, not recruiting Phase 2

Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

NCT07651475 · tracked via the Priya Life Science China tracker
Sponsor
Liping Dou
Phase
Phase 2
Started
2026-03-31
Last updated
2026-06-16

Condition(s) studied

R/R AML

Investigational drug(s) / intervention(s)

BCL-2 inhibitor, Zemestosita, Azacitidine, Cytarabine, Chidamide, and G-CSF

BCL-2 inhibitor, Zemestosita, Azacitidine, Cytarabine, Chidamide, and G-CSF: BCL-2 inhibitor, Zemestosita, Azacitidine, Cytarabine, chidamide, and G-CSF

Study summary

The purpose of this study is to determine the efficacy and safety of the Beach regimen on relapsed/refractory acute myeloid leukemia

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: 1. Age 18-75 years 2. Confirmed diagnosis of R/R AML 3. Adequate organ function: TBIL ≤2×ULN; ALT/AST ≤2.5×ULN; Cr ≤ULN or Ccr ≥50 mL/min 4. ECOG performance status ≤2 5. Life expectancy ≥4 months 6. No severe allergic history 7. Not participating in other interventional trials during study 8. Signed informed consent - Exclusion Criteria: 1. Hypersensitivity to any study drug 2. Dysphagia or uncontrolled gastrointestinal disease impairing oral intake 3. Acute promyelocytic leukemia (APL) 4. Prior treatment with EZH1/2 inhibitors 5. Allogeneic hematopoietic stem cell transplantation within 6 months 6. Participation in another interventional trial within 4 weeks 7. Smoking and excessive drinking have affected the evaluation of the test results; 8. Undergone major organ surgery within the previous 6 weeks and whose recovery was not complete 9. Severe chronic respiratory disease requiring continuous oxygen 10. Clinically significant cardiac, renal, hepatic, neurologic, or endocrine disease; Child-Pugh B/C cirrhosis 11. Active uncontrolled infection including HBV, HCV, HIV, syphilis 12. Pregnant or breastfeeding women; women planning pregnancy during study 13. The patients deemed unsuitable by the researchers to participate in this study. -

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Chinese PLA General Hospital Beijing Beijing Municipality

More Liping Dou trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07651475 on ClinicalTrials.gov ↗ ← All trials in China